{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:40:43Z","timestamp":1768995643273,"version":"3.49.0"},"reference-count":40,"publisher":"ALUNA","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:p>At the beginning of 2020, the world was faced with the challenge of the coronavirus disease 2019 (COVID-19) pandemic announced by the WHO on March 11, caused by the betacoronavirus type 2 of the severe acute respiratory syndrome (SARS-CoV-2), which had profound health, sociological and even economic consequences. The quickly implemented and large-scale research resulted in the introduction of widely available vaccines that reduced the further development of the pandemic and antivirals against SARS-CoV-2. Currently, 11 antiviral drugs (Tixagevimab\/Cilgavimab, Regdanvimab, Casirivimab\/Imdevimab, Sotrovimab, Nirmatrelvir\/Ritonavir, Remdesivir, Molnupiravir, Baricitinib, Anakinra, Tocilizumab, Vilobelimab) have been approved or conditionally approved by the European Medicines Agency and\/or by the Food and Drug Administration and are available on the pharmaceutical market. The progress in the pathophysiological description of the SARS-CoV-2 infection has allowed the identif i cation of potential targets for drugs against SARS-CoV-2: inhibitors of intracellular entry of the virus (the interaction between the viral spike (S) protein and the cellular angiotensin converting enzyme-2; ACE2 receptor), inhibitors of viral and cellular proteases, and immunomodulatory drugs (antagonists of pro-inf l ammatory cytokines or complement components). Novel agents against SARS-CoV-2 are also sought among the previously routinely used drugs as their repositioning and among plant-derived compounds. It is expected that ongoing research should result in the introduction of new drugs used in COVID-19 in the near future. The article brief l y describes the current epidemiological situation regarding COVID-19 and the currently used vaccines. Moreover, the paper outlines currently used and researched potential drugs in the pharmacotherapy of this disease.<\/jats:p>","DOI":"10.36740\/merkur202403111","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T11:58:32Z","timestamp":1721044712000},"page":"337-346","source":"Crossref","is-referenced-by-count":1,"title":["A review on the current approaches and perspectives of Covid-19 treatment"],"prefix":"10.36740","volume":"52","author":[{"given":"\u0141ukasz","family":"Dobrek","sequence":"first","affiliation":[{"name":"FACULTY OF SCIENCE AND TECHNOLOGY, JAN DLUGOSZ UNIVERSITY IN CZESTOCHOWA, CZESTOCHOWA, POLAND"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomed J. 2020;43(4):328-333. doi: 10.1016\/j.bj.2020.04.007.","DOI":"10.1016\/j.bj.2020.04.007"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. Patil SR, Patil PS, Rajput PL et al. A history of global pandemic from 20th century to novel emerging human corona virus SARS-CoV-2. Health Sci J. 2022;16(9):969.","DOI":"10.4103\/jihs.jihs_16_21"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Ahammed T, Anjum A, Rahman MM et al. Estimation of novel coronavirus (COVID-19) reproduction number and case fatality rate: A systematic review and meta-analysis. Health Sci Rep. 2021;4(2):e274. doi: 10.1002\/hsr2.274.","DOI":"10.1101\/2020.09.30.20204644"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Carvalho T, Krammer F, Iwasaki A. The fi rst 12 months of COVID-19: a timeline of immunological insights. Nat Rev Immunol. 2021;21(4):245-256. doi: 10.1038\/s41577-021-00522-1.","DOI":"10.1038\/s41577-021-00522-1"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Marcian\u00f2 G, Roberti R, Palleria C et al. SARS-CoV-2 treatment: Current therapeutic options and the pursuit of tailored therapy. Appl Sci. 2021;11:7457. doi: 10.3390\/app11167457.","DOI":"10.3390\/app11167457"},{"key":"ref5","unstructured":"6. World Health Organization. WHO Covid-19 dashboard. https:\/\/data.who.int\/dashboards\/covid19\/cases?n=c [Access: 2024 February 4]"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Serwis Rzeczypospolitej Polskiej. Raport zaka\u017ce\u0144 koronawirusem (SARS-CoV-2). Website of the Republic of Poland. Coronavirus infection report (SARS-CoV-2). https:\/\/www.gov.pl\/web\/koronawirus\/wykaz-zarazen-koronawirusem-sars-cov-2 [Access: 2024 February 4] (Polish).","DOI":"10.24292\/01.mf.0120.3"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Fan Y, Li X, Zhang L et al. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022;7(1):141. doi: 10.1038\/ s41392-022-00997-x.","DOI":"10.1038\/s41392-022-00997-x"},{"key":"ref8","unstructured":"9. World Health Organization. Tracking SARS-CoV-2 variants. https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants [Access: 2024 February 4]"},{"key":"ref9","unstructured":"10. European Centre for Disease Prevention and Control. Covid-19. Latest news and reports. https:\/\/www.ecdc.europa.eu\/en\/covid-19 [Access: 2024 February 4]"},{"key":"ref10","unstructured":"11. Centers for Disease Control and Prevention. COVID data tracker. Summary of variant surveillance. https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-sum-mary [Access: 2024 February 4]"},{"key":"ref11","unstructured":"12. Gomo\u0142a K W Polsce dominuje teraz nowy wariant COVID-19. Objawy s\u0105 inne ni\u017c wcze\u015bniej [A new variant of COVID-19 is now dominant in Poland. The symptoms are dif f erent than before] https:\/\/www.medonet.pl\/koronawirus\/to-musisz-wiedziec,w-polsce-dominuje-teraz-nowy-wariant-covid-19- objawy-sa-inne-niz-wczesniej,artykul,17082050.html [Access: 2024 February 4] (Polish)."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. World Health Organization. Statement on the fi fteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. https:\/\/www.who.int\/news\/item\/05-05-2023-statement-on-the-f i fteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regard-ing-the-coronavirus-disease-(covid-19)-pandemic [Access: 2024 February 4]","DOI":"10.4178\/epih.e2020013"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Zhu Y, Sharma L, Chang D. Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review. Front Immunol. 2023;14:1116131. doi: 10.3389\/f i mmu.2023.1116131.","DOI":"10.3389\/fimmu.2023.1116131"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Shi T, Robertson C, Sheikh A. Ef f ectiveness and safety of coronavirus disease 2019 vaccines. Curr Opin Pulm Med. 2023;29(3):138-142. doi: 10.1097\/ MCP.0000000000000948.","DOI":"10.1097\/MCP.0000000000000948"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Lamprinou M, Sachinidis A, Stamoula E et al. COVID-19 vaccines adverse events: potential molecular mechanisms. Immunol Res. 2023;71(3):356-372. doi: 10.1007\/s12026-023-09357-5.","DOI":"10.1007\/s12026-023-09357-5"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Finsterer J. Neurological adverse reactions to SARS-CoV-2 vaccines. Clin Psychopharmacol Neurosci. 2023;21(2):222-239. doi: 10.9758\/cpn.2023.21.2.222.","DOI":"10.9758\/cpn.2023.21.2.222"},{"key":"ref17","unstructured":"18. World Health Organization. COVID-19 vaccination, world data. https:\/\/data.who.int\/dashboards\/covid19\/vaccines?n=c [Access: 2024 February 4]"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Khalid K, Poh CL. The development of DNA vaccines against SARS-CoV-2. Adv Med Sci. 2023;68(2):213-226. doi: 10.1016\/j.advms.2023.05.003.","DOI":"10.1016\/j.advms.2023.05.003"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Lupa\u0219cu RE, Ilie MI, Velescu B\u0218 et al. COVID-19-current therapeutical approaches and future perspectives. Processes. 2022;10:1053. doi: 10.3390\/pr10061053.","DOI":"10.3390\/pr10061053"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. European Medicines Agency. COVID-19 medicines. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/coronavirus-dis-ease-covid-19\/covid-19-medicines [Access: 2024 February 4]","DOI":"10.4324\/9781003139140-19"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. U.S. Food and Drug Administration. Coronavirus (COVID-19) drugs. https:\/\/www.fda.gov\/drugs\/emergency-preparedness-drugs\/coronavirus-covid-19-drugs [Access: 2024 February 4]","DOI":"10.26434\/chemrxiv.11847381"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23. Raghav PK, Mann Z, Ahluwalia SK et al. Potential treatments of COVID-19: Drug repurposing and therapeutic interventions. J Pharmacol Sci. 2023;152(1):1-21. doi: 10.1016\/j.jphs.2023.02.004.","DOI":"10.1016\/j.jphs.2023.02.004"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Srivastava V, Ahmad A. New perspective towards therapeutic regimen against SARS-CoV-2 infection. J Infect Public Health. 2021;14(7):852-862. doi: 10.1016\/j.jiph.2021.05.009.","DOI":"10.1016\/j.jiph.2021.05.009"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Kakavandi S, Zare I, VaezJalali M et al. Structural and non-structural proteins in SARS-CoV-2: Potential aspects to COVID-19 treatment or prevention of progression of related diseases. Cell Commun Signal. 2023;21(1):110. doi: 10.1186\/s12964-023-01104-5.","DOI":"10.1186\/s12964-023-01104-5"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Platto S, Wang Y, Zhou J et al. History of the COVID-19 pandemic: Origin, explosion, worldwide spreading. Biochem Biophys Res Commun. 2021;538:14-23. doi: 10.1016\/j.bbrc.2020.10.087.","DOI":"10.1016\/j.bbrc.2020.10.087"},{"key":"ref26","unstructured":"27. Ochani R, Asad A, Yasmin F et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med. 2021;29(1):20-36."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28. Saxena PS, Singh K, Jangir P et al. Perspectives for potential therapies for SARS-CoV-2: Review of the present literature. IJQSPR 2021;6(4):1-24. doi: 10.4018\/ IJQSPR.2021100101.","DOI":"10.4018\/IJQSPR.2021100101"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Li G, Hilgenfeld R, Whitley R et al. Therapeutic strategies for COVID-19: Progress and lessons learned. Nat Rev Drug Discov. 2023;22:449-475. doi: 10.1038\/ s41573-023-00672-y","DOI":"10.1038\/s41573-023-00672-y"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Xiang R, Yu Z, Wang Y et al. Recent advances in developing small-molecule inhibitors against SARS-CoV-2. Acta Pharm Sin B. 2022;12(4):1591-1623. doi: 10.1016\/j.apsb.2021.06.016.","DOI":"10.1016\/j.apsb.2021.06.016"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Wang RS, Loscalzo J. Repurposing drugs for the treatment of COVID-19 and its cardiovascular manifestations. Circ Res. 2023;132(10):1374-1386. doi: 10.1161\/CIRCRESAHA.122.321879. Erratum in: Circ Res. 2023;133(3):e49.","DOI":"10.1161\/circresaha.122.321879"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Rodrigues L, Bento Cunha R, Vassilevskaia T et al. Drug repurposing for COVID-19: A review and a novel strategy to identify new targets and potential drug candidates. Molecules. 2022;27(9):2723. doi: 10.3390\/molecules27092723.","DOI":"10.3390\/molecules27092723"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Niknam Z, Jafari A, Golchin A et al. Potential therapeutic options for COVID-19: An update on current evidence. Eur J Med Res. 2022;27(1):6. doi: 10.1186\/ s40001-021-00626-3.","DOI":"10.1186\/s40001-021-00626-3"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Ashirmetov AK. Pharmacotherapeutic treatment strategies COVID-19: Lessons learned and perspectives. Explor Res Hypothesis Med. 2023;8(1):36-47. doi: 10.14218\/ERHM.2022.00034.","DOI":"10.14218\/erhm.2022.00034"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35. Kif l e ZD, Ayele AG, Enyew EF. Drug repurposing approach, potential drugs, and novel drug targets for COVID-19 treatment. J Environ Public Health. 2021;2021:Article ID 6631721. https:\/\/doi.org\/10.1155\/2021\/6631721.","DOI":"10.1155\/2021\/6631721"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. Kim CH. Anti-SARS-CoV-2 natural products as potentially therapeutic agents. Front Pharmacol. 2021;12:590509. doi: 10.3389\/fphar.2021.590509.","DOI":"10.3389\/fphar.2021.590509"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37. Vel\u00e1squez PA, Hernandez JC, Galeano E et al. Ef f ectiveness of drug repurposing and natural products against SARS-CoV-2: A comprehensive review. Clin Pharmacol. 2024;16:1-25. doi: 10.2147\/CPAA.S429064.","DOI":"10.2147\/cpaa.s429064"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. Low Z, Lani R, Tiong V et al. COVID-19 therapeutic potential of natural products. Int J Mol Sci. 2023;24(11):9589. doi: 10.3390\/ijms24119589.","DOI":"10.3390\/ijms24119589"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39. Kim TH, Kang JW, Jeon SR et al. Use of traditional, complementary and integrative medicine during the COVID-19 pandemic: A systematic review and meta-analysis. Front Med (Lausanne). 2022;9:884573. doi: 10.3389\/fmed.2022.884573.","DOI":"10.3389\/fmed.2022.884573"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. Boretti A, Banik B, Castelletto S. Use of ultraviolet blood irradiation against viral infections. Clin Rev Allergy Immunol. 2021;60(2):259-270. doi: 10.1007\/ s12016-020-08811-8.","DOI":"10.1007\/s12016-020-08811-8"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T07:32:40Z","timestamp":1724916760000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2024i3lq.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024]]},"published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202403111","archive":["Internet Archive"],"relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}